APPLICANT Hotta, et al. FILING DATE 09/25/03 U.S. PATENT DOCUMENTS	FORM PTO-1	449	U.S. DEPARTMENT				DKT NO.			AL NO.	
STATEMENT BY APPLICANT U.S. PATENT DOCUMENTS	KA C .	70	PATENT AND TRADEMARK OFFICE								
U.S. PATENT DOCUMENTS	\O \\@										
STATEMENT BY APPLICANT	1 3/1.	SINI	FORMATION DIS	SCLOSURE	,					JР	
DOCUMENT NO. DATE NAME CL. SUBCL. FILING DATE NAME P1 US 2002/0192794 12/19/02 Dadd, et al. 435 217 P2 US 2002/0009707 01/24/02 Nur, et al. 435 2 P3 6,096,872 A 08/01/00 Van Holten, et al. 530 390.1 P4 5,886,154 03/23/99 Lebing, et al. 530 390.1 P4 5,886,154 03/23/99 Lebing, et al. 530 390.1 P5 2,390,074 12/04/45 Cohn, et al. 260 122 P6 P7 P7 P8 P8 P8 P8 P8 P8	MAI					09/25/0	3		3762		
NITIAL	PATENT & TR	ACCE		U.S. PATI	ENT DOCUMENTS	.					
ADK P2 US 2002/0009707 01/24/02 Nur, et al. P3 6,096,872 A 08/01/00 Van Holten, et al. 530 390.1 P4 5,886,154 03/23/99 Lebing, et al. 530 390.1 ADK P5 2,390,074 12/04/45 Cohn, et al. 260 122 FOREIGN PATENT DOCUMENTS DOCUMENT NO. DATE COUNTRY CL. SUBCL TRANSLATION ADK F1 EP 1 206 961 A1 05/22/02 EP ADK P3 WO 98/37086 08/27/98 WO OTHER DOCUMENTS (Incl. Author, Title, Date, Pertinent pages, etc.) ADK F3 WO 98/37086 08/27/98 WO OTHER DOCUMENTS (Incl. Author, Title, Date, Pertinent pages, etc.) ADK B1 Ab, H., et al., "Removal of Parovovins B19 from Hemoglobin Solution by Nanofiltration," Arx. Cells, Blood Subs., and Immob. Biotech., 28(5): 375-383 (2000). D2 Aranha, H., "Viral Clearance Strategies for Biopharmaceutical Safety Part 2: Filtration for Viral Clearance," Reprinted from Biopharm, 8 pages (2001). D3 Burnouf Radosevich, M., et al., "Nanofiltration, a New Specific Virus Elimination Method Applied to High-Purity Factor IX and Factor XI Concentrates," Vox. Sang., 67(I): 132-138 (1994). D4 Burnouf Radosevich, M., "Viral Safety of Intravenous Immunglobulins of for Therapeutic Use," Transfus. Clim. Biol., 2(3): 167-179 (1995). D5 Carter, I., and H. Lutz, "An overview of viral filtration in biopharmaceutical manufacturing," European Journal of Parenteral Sciences, 7(3): 72-78 (2002). D6 Hotta, J., et al., "Significant Parvovirus Removal and Product Recovery from an IgG-containing Solution using Planova Filters," PDA/FDA Viral Clearance Forum, I page (October 2001). D8 Komeyeva, M., "Factors Influencing Virus Removal and Product Yield During Nanofiltration of Highly Purified Plasma-Derived Protein with Thrombolytic Activity," Slides from Oral Presentation, 29th World Congress of the International Society of Hematology, Seoul, Korea, pp. 1-17 (August 24-28, 2002). D9 Li, H., et al., "Low pH of Feed Solutions Significantly Increases Procine Parvovirus Aggregate Formation," Slides from Oral Presentation, PDA/FDA Viral Clearance Forum, Washington, DC, pp. 1-18 (October 1-3, 2001). DADA DA DA DA DA D	EXAMINER INITIAL				NAME		CL.	SU	BCL.		
P3 6,096,872 A 08/01/00 Van Holten, et al. 530 390.1 P4 5,886,154 03/23/99 Lebing, et al. 530 390.1 P6 2,390,074 12/04/45 Cohn, et al. 260 122 FOREIGN PATENT DOCUMENTS DOCUMENT NO. DATE COUNTRY CL. SUBCL TRANSLATION ADK F1 EP 1206 961 A1 05/22/02 EP ADK F2 WO 01/36611 A1 05/25/01 WO ADK F3 WO 98/37086 08/27/98 WO OTHER DOCUMENTS (Incl. Author, Title, Date, Pertinent pages, etc.) ADK B4 H, et al., "Removal of Parvovirus B19 from Hemoglobin Solution by Nanofiltration," Art. Cells, Blood Subs., and Immob. Biotech., 28(5): 375-383 (2000). D2 Aranha, H., "Viral Clearance Strategies for Biopharmaceutical Safety Part 2: Filtration for Viral Clearance," Reprinted from Blopharm, 8 pages (2001). D3 Burnouf-Radosevich, M., et al., "Nanofiltration, a New Specific Virus Elimination Method Applied to High-Purity Pator IX and Factor XI Concentrates," Vox. Sang., 67(1): 132-138 (1994). D4 Burnouf-Radosevich, M., "Viral Safety of Intravenous Immunglobulins G for Therapeutic Use," Transfus. Clin. Biol., 2(3): 167-179 (1995). D5 Carter, J., and H. Lutz, "An overview of viral filtration in biopharmaceutical manufacturing," European Journal of Parenteral Sciences, 7(3): 72-78 (2002). D6 Hotta, J., et al., "Significant Parvovirus Removal and Product Recovery from an IgG-containing Solution using Planova Filters," PDA/FDA Viral Clearance Forum, 1 page (October 2001). D7 Ide, S., "Development of New Planova® Membrane – the Planova® 20N Filter," Planova® Workshop Tokyo, Japan, pp. 135-145 (November 1, 2000). D8 Kormeyeva, M., "Factors Influencing Virus Removal and Product Yield During Nanofiltration of Highly Purified Plasma-Derived Protein with Thrombolytic Activity," Sildes from Oral Presentation, 29th World Congress of the International Society of Hematology, Seoul, Korea, pp. 1-17 (August 24-28, 2002). D9 Li, H., et al., "Low pH of Feed Solutions Significantly Increases Procine Parvovirus Aggregate Formation," Sildes from Oral Presentation, PDA/FDA Viral Clearance Forum, Washington, DC, pp. 1-12 (October 1-3, 2001)	ADK	Pl	Al	12/19/02	Dadd, et al.		435	217			
P4 5,886,154 03/23/99 Lebing, et al. 530 390.1 P5 2,390,074 12/04/45 Cohn, et al. 260 172 FOREIGN PATENT DOCUMENTS FOREIGN PATENT DOCUMENTS DOCUMENT NO. DATE COUNTRY CL. SUBCL TRANSLATION ADK F1 EP 1206 961 A1 05/22/02 EP ADK F2 WO 01/36611 A1 05/25/01 WO ADK F3 WO 98/37086 08/27/98 WO OTHER DOCUMENTS (Incl. Author, Title, Date, Pertinent pages, etc.) ADK B1 WO 98/37086 08/27/98 WO OTHER DOCUMENTS (Incl. Author, Title, Date, Pertinent pages, etc.) ADK B1 WO 98/37086 08/27/98 WO OTHER DOCUMENTS (Incl. Author, Title, Date, Pertinent pages, etc.) ADK B1 WO 98/37086 08/27/98 WO OTHER DOCUMENTS (Incl. Author, Title, Date, Pertinent pages, etc.) ADK B1 WO 98/37086 08/27/98 WO OTHER DOCUMENTS (Incl. Author, Title, Date, Pertinent pages, etc.) ADK B1 WO 98/37086 08/27/98 WO OTHER DOCUMENTS (Incl. Author, Title, Date, Pertinent pages, etc.) ADK B1 WO 98/37086 08/27/98 WO OTHER DOCUMENTS (Incl. Author, Title, Date, Pertinent pages, etc.) ADK B1 WO 98/37086 08/27/98 WO OTHER DOCUMENTS (Incl. Author, Title, Date, Pertinent pages, etc.) ADK B1 WO 98/37086 08/27/98 WO OTHER DOCUMENTS (Incl. Author, Title, Date, Pertinent pages, etc.) ADK B1 WO 98/37086 08/27/98 WO OTHER DOCUMENTS (Incl. Author, Title, Date, Pertinent pages, etc.) ADK B1 WO 98/37086 08/27/98 WO OTHER DOCUMENTS (Incl. Author, Title, Date, Pertinent pages, etc.) ADK B1 WO 98/37086 08/27/98 WO OTHER DOCUMENTS (Incl. Author, Title, Date, Pertinent pages, etc.) ADK B1 W0 98/37086 08/27/98 WO OTHER DOCUMENTS (Incl. Author, Title, Date, Pertinent pages, etc.) ADK B1 W1		P2	A1		Nur, et al.		435	2	•		
FOREIGN PATENT DOCUMENTS DOCUMENT NO. DATE		P3	6,096,872 A	08/01/00	Van Holten, et al.		530	390.	1		
FOREIGN PATENT DOCUMENTS DOCUMENT NO. DATE COUNTRY CL. SUBCL TRANSLATION ADK F1 EP 1 206 961 A1 05/22/02 EP ADK F2 WO 01/36611 A1 05/22/01 WO ADK F3 WO 98/37086 08/27/98 WO OTHER DOCUMENTS (Incl. Author, Title, Date, Pertinent pages, etc.) ADK D1 Abe, H., et al., "Removal of Parvovirus B19 from Hemoglobin Solution by Nanofiltration," Art. Cells, Blood Subs., and Immob. Biotech., 28(5): 375-383 (2000). D2 Aranha, H., "Viral Clearance Strategies for Biopharmaceutical Safety Part 2: Filtration for Viral Clearance," Reprinted from Biopharm., 8 pages (2001). D3 Burnouf-Radosevich, M., et al., "Nanofiltration, a New Specific Virus Elimination Method Applied to High-Purity Factor IX and Factor XI Concentrates," Vox. Sang., 67(1): 132-138 (1994). D4 Burnouf-Radosevich, M., "Viral Safety of Intravenous Immunglobulins G for Therapeutic Use," Transfus. Clin. Biol., 2(3): 167-179 (1995). D5 Carter, J., and H. Lutz, "An overview of viral filtration in biopharmaceutical manufacturing," European Journal of Parenteral Sciences, 7(3): 72-78 (2002). D6 Hotta, J., et al., "Significant Parvovirus Removal and Product Recovery from an IgG-containing Solution using Planova Filters," PDA/FDA Viral Clearance Forum, 1 page (October 2001). D7 Ide, S., "Development of New Planova® Membrane — the Planova® 20N Filter," Planova® Workshop Tokyo, Japan, pp. 135-145 (November 1, 2000). D8 Korneyeva, M., "Factors Influencing Virus Removal and Product Yield During Nanofiltration of Highly Purified Plasma-Derived Protein with Thrombolytic Activity," Slides from Oral Presentation, 29th World Congress of the International Society of Hematology, Seoul, Korea, pp. 1-17 (August 24-28, 2002). D9 Li, H., et al., "Low pH of Feed Solutions Significantly Increases Procine Parvovirus Aggregate Formation," Slides from Oral Presentation, PDA/FDA Viral Clearance Forum, Washington, DC, pp. 1-18 (October 1-3, 2001). D10 McNaull, S., et al., "Parvovirus Removal from an IgG-containing Solution at Extended Challenge Volume Using an Ultrafiltration Mem	V		5,886,154	03/23/99	Lebing, et al.		530	390.	1		
ADK F1 EP 1206 961 A1 05/22/02 EP WO 01/36611 A1 05/22/02 EP WO 01/36611 A1 05/22/02 EP WO 01/36611 A1 05/22/01 WO ADR F2 WO 01/36611 A1 05/25/01 WO OTHER DOCUMENTS (Incl. Author, Title, Date, Pertinent pages, etc.) ADR D1 Abe, H., et al., "Removal of Parvovirus B19 from Hemoglobin Solution by Nanofiltration," Art. Cells, Blood Subs., and Immob. Biotech., 28(5): 375-383 (2000). Aranha, H., "Viral Clearance Strategies for Biopharmaceutical Safety Part 2: Filtration for Viral Clearance," Reprinted from Biopharm., 8 pages (2001). D3 Burnouf-Radosevich, M., et al., "Nanofiltration, a New Specific Virus Elimination Method Applied to High-Purity Factor IX and Factor XI Concentrates," Vox. Sang., 67(1): 132-138 (1994). D4 Burnouf-Radosevich, M., "Viral Safety of Intravenous Immunglobulins G for Therapeutic Use," Transfus. Clin. Biol., 2(3): 167-179 (1995). D5 Carter, J., and H. Lutz, "An overview of viral filtration in biopharmaceutical manufacturing," European Journal of Parenteral Sciences, 7(3): 72-78 (2002). D6 Hotta, J., et al., "Significant Parvovirus Removal and Product Recovery from an IgG-containing Solution using Planova Filters," PDA/FDA Viral Clearance Forum, 1 page (October 2001). D7 Ide, S., "Development of New Planova® Membrane – the Planova® 20N Filter," Planova® Workshop Tokyo, Japan, pp. 135-145 (November 1, 2000). D8 Korneyeva, M., "Factors Influencing Virus Removal and Product Yield During Nanofiltration of Highly Purified Plasma-Derived Protein with Thrombolytic Activity," Slides from Oral Presentation, 29th World Congress of the International Society of Hematology, Seoul, Korea, pp. 1-17 (August 24-28, 2002). D9 Li, H., et al., "Low pH of Feed Solutions Significantly Increases Procine Parvovirus Aggregate Formation," Slides from Oral Presentation, PDA/FDA Viral Clearance Forum, Washington, DC, pp. 1-18 (October 1-3, 2001). D10 McNaull, S., et al., "Parvovirus Removal from an IgG-containing Solution at Extended Challenge Volume Using an Ultrafiltration Membrane in Normal-Flow Configura	ADK	P5	2,390,074	12/04/45	Cohn, et al.		260	122			-
ADK F1 EP 1206 961 A1 05/22/02 EP WO 01/36611 A1 05/22/02 EP WO 01/36611 A1 05/22/02 EP WO 01/36611 A1 05/22/01 WO ADR F2 WO 01/36611 A1 05/25/01 WO OTHER DOCUMENTS (Incl. Author, Title, Date, Pertinent pages, etc.) ADR D1 Abe, H., et al., "Removal of Parvovirus B19 from Hemoglobin Solution by Nanofiltration," Art. Cells, Blood Subs., and Immob. Biotech., 28(5): 375-383 (2000). Aranha, H., "Viral Clearance Strategies for Biopharmaceutical Safety Part 2: Filtration for Viral Clearance," Reprinted from Biopharm., 8 pages (2001). D3 Burnouf-Radosevich, M., et al., "Nanofiltration, a New Specific Virus Elimination Method Applied to High-Purity Factor IX and Factor XI Concentrates," Vox. Sang., 67(1): 132-138 (1994). D4 Burnouf-Radosevich, M., "Viral Safety of Intravenous Immunglobulins G for Therapeutic Use," Transfus. Clin. Biol., 2(3): 167-179 (1995). D5 Carter, J., and H. Lutz, "An overview of viral filtration in biopharmaceutical manufacturing," European Journal of Parenteral Sciences, 7(3): 72-78 (2002). D6 Hotta, J., et al., "Significant Parvovirus Removal and Product Recovery from an IgG-containing Solution using Planova Filters," PDA/FDA Viral Clearance Forum, 1 page (October 2001). D7 Ide, S., "Development of New Planova® Membrane – the Planova® 20N Filter," Planova® Workshop Tokyo, Japan, pp. 135-145 (November 1, 2000). D8 Korneyeva, M., "Factors Influencing Virus Removal and Product Yield During Nanofiltration of Highly Purified Plasma-Derived Protein with Thrombolytic Activity," Slides from Oral Presentation, 29th World Congress of the International Society of Hematology, Seoul, Korea, pp. 1-17 (August 24-28, 2002). D9 Li, H., et al., "Low pH of Feed Solutions Significantly Increases Procine Parvovirus Aggregate Formation," Slides from Oral Presentation, PDA/FDA Viral Clearance Forum, Washington, DC, pp. 1-18 (October 1-3, 2001). D10 McNaull, S., et al., "Parvovirus Removal from an IgG-containing Solution at Extended Challenge Volume Using an Ultrafiltration Membrane in Normal-Flow Configura				FOREIGN PA	ATENT DOCUMEN	NTS					
ADK F1 EP 1 206 961 A1 05/22/02 EP ADK F2 WO 01/36611 A1 05/25/01 WO ADK F3 WO 98/37086 08/27/98 WO OTHER DOCUMENTS (Incl. Author, Title, Date, Pertinent pages, etc.) ADK D1 Abe, H., et al., "Removal of Parvovirus B19 from Hemoglobin Solution by Nanofiltration," Art. Cells, Blood Subs., and Immob. Biotech., 28(5): 375-383 (2000). D2 Aranha, H., "Viral Clearance Strategies for Biopharmaceutical Safety Part 2: Filtration for Viral Clearance," Reprinted from Biopharm. 8 pages (2001). D3 Burmouf-Radosevich, M., et al., "Nanofiltration, a New Specific Virus Elimination Method Applied to High-Purity Factor IX and Factor XI Concentrates," Yox. Sang., 67(1): 132-138 (1994). D4 Burmouf-Radosevich, M., "Viral Safety of Intravenous Immunglobulins G for Therapeutic Use," Transfus. Clin. Biol., 2(3): 167-179 (1995). D5 Carter, J., and H. Lutz, "An overview of viral filtration in biopharmaceutical manufacturing," European Journal of Parenteral Sciences, 7(3): 72-78 (2002). D6 Hotta, J., et al., "Significant Parvovirus Removal and Product Recovery from an IgG-containing Solution using Planova Filters," PDA/FDA Viral Clearance Forum, 1 page (October 2001). D7 Ide, S., "Development of New Planova® Membrane - the Planova® 20N Filter," Planova® Workshop Tokyo, Japan, pp. 135-145 (November 1, 2000). D8 Korneyeva, M., "Factors Influencing Virus Removal and Product Yield During Nanofiltration of Highly Purified Plasma-Derived Protein with Thrombolytic Activity," Slides from Oral Presentation, 29 th World Congress of the International Society of Hematology, Seoul, Korea, pp. 1-17 (August 24-28, 2002). D10 McNaull, S., et al., "Day H of Feed Solutions Significantly Increases Procine Parvovirus Aggregate Formation," Slides from Oral Presentation, PDA/FDA Viral Clearance Forum, Washington, DC, pp. 1-18 (October 1-3, 2001). D10 McNaull, S., et al., "Parvovirus Removal from an IgG-containing Solution at Extended Challenge Volume Using an Ultrafiltration Membrane in Normal-Flow Configuration," Slides from Oral Presentation,		Τ	DOCUMENT NO.				CL.	SUBO	CLT	TRANS	LATION
ADK F2 WO 01/36611 A1 05/25/01 WO ADK F3 WO 98/37086 08/27/98 WO OTHER DOCUMENTS (Incl. Author, Title, Date, Pertinent pages, etc.) ADR D1 Abe, H., et al., "Removal of Parvovirus B19 from Hemoglobin Solution by Nanofiltration," Art. Cells, Blood Subs., and Immob. Biotech., 28(5): 375-333 (2000). D2 Aranha, H., "Viral Clearance Strategies for Biopharmaceutical Safety Part 2: Filtration for Viral Clearance," Reprinted from Biopharm., 8 pages (2001). D3 Burnouf-Radosevich, M., et al., "Nanofiltration, a New Specific Virus Elimination Method Applied to High-Purity Factor IX and Factor XI Concentrates," Yox. Sang., 67(1): 132-138 (1994). D4 Burnouf-Radosevich, M., "Viral Safety of Intravenous Immunglobulins G for Therapeutic Use," Transfus. Clin. Biol., 2(3): 167-179 (1995). D5 Carter, J., and H. Lutz, "An overview of viral filtration in biopharmaceutical manufacturing," European Journal of Parenteral Sciences, 7(3): 72-78 (2002). D6 Hotta, J., et al., "Significant Parvovirus Removal and Product Recovery from an IgG-containing Solution using Planova Filters," PDA/FDA Viral Clearance Forum, 1 page (October 2001). D7 Ide, S., "Development of New Planova® Membrane – the Planova® 20N Filter," Planova® Workshop Tokyo, Japan, pp. 135-145 (November 1, 2000). D8 Korneyeva, M., "Factors Influencing Virus Removal and Product Yield During Nanofiltration of Highly Purified Plasma-Derived Protein with Thrombolytic Activity," Slides from Oral Presentation, 29th World Congress of the International Society of Hematology, Seoul, Korea, pp. 1-17 (August 24-28, 2002). D9 Li, H., et al., "Low pH of Feed Solutions Significantly Increases Procine Parvovirus Aggregate Formation," Slides from Oral Presentation, PDA/FDA Viral Clearance Forum, Washington, DC, pp. 1-18 (October 1-3, 2001). M6Naull, S., et al., "Parvovirus Removal from an IgG-containing Solution at Extended Challenge Volume Using an Ultrafiltration Membrane in Normal-Flow Configuration," Slides from Oral Presentation, PDA/FDA Viral Clearance Forum, Washington, DC,	ADK	FI.									
ADK F3 WO 98/37086 08/27/98 WO OTHER DOCUMENTS (Incl. Author, Title, Date, Pertinent pages, etc.) ADK D1 Abe, H., et al., "Removal of Parvovirus B19 from Hemoglobin Solution by Nanofiltration," Art. Cells, Blood Subs., and Immob. Biotech., 28(5): 375-383 (2000). D2 Aranha, H., "Viral Clearance Strategies for Biopharmaceutical Safety Part 2: Filtration for Viral Clearance," Reprinted from Biopharm., 8 pages (2001). D3 Burnouf-Radosevich, M., et al., "Nanofiltration, a New Specific Virus Elimination Method Applied to High-Purity Factor IX and Factor XI Concentrates," Yox. Sang., 67(1): 132-138 (1994). D4 Burnouf-Radosevich, M., "Viral Safety of Intravenous Immunglobulins G for Therapeutic Use," Transfus. Clin. Biol., 2(3): 167-179 (1995). D5 Carter, J., and H. Lutz, "An overview of viral filtration in biopharmaceutical manufacturing," European Journal of Parenteral Sciences, 7(3): 72-78 (2002). D6 Hotta, J., et al., "Significant Parvovirus Removal and Product Recovery from an IgG-containing Solution using Planova Filters," PDA/FDA Viral Clearance Forum, 1 page (October 2001). D7 Ide, S., "Development of New Planova® Membrane – the Planova® 20N Filter," Planova® Workshop Tokyo, Japan, pp. 135-145 (November 1, 2000). D8 Korneyeva, M., "Factors Influencing Virus Removal and Product Yield During Nanofiltration of Highly Purified Plasma-Derived Protein with Thrombolytic Activity," Slides from Oral Presentation, 29th World Congress of the International Society of Hematology, Seoul, Korea, pp. 1-17 (August 24-28, 2002). D9 Li, H., et al., "Low pH of Feed Solutions Significantly Increases Procine Parvovirus Aggregate Formation," Slides from Oral Presentation, PDA/FDA Viral Clearance Forum, Washington, DC, pp. 1-18 (October 1-3, 2001). McNaull, S., et al., "Parvovirus Removal from an IgG-containing Solution at Extended Challenge Volume Using an Ultrafiltration Membrane in Normal-Flow Configuration," Slides from Oral Presentation, PDA/FDA Viral Clearance Forum, Washington, DC, pp. 1-12 (October 1-3, 2001). DATE			.l	1	wo				\dashv	-	
ADK D1 Abe, H., et al., "Removal of Parvovirus B19 from Hemoglobin Solution by Nanofiltration," Art. Cells, Blood Subs., and Immob. Biotech., 28(5): 375-383 (2000). D2 Aranha, H., "Viral Clearance Strategies for Biopharmaceutical Safety Part 2: Filtration for Viral Clearance," Reprinted from Biopharm., 8 pages (2001). D3 Burnouf-Radosevich, M., et al., "Nanofiltration, a New Specific Virus Elimination Method Applied to High-Purity Factor IX and Factor XI Concentrates," Yox. Sang., 67(I): 132-138 (1994). D4 Burnouf-Radosevich, M., "Viral Safety of Intravenous Immunglobulins G for Therapeutic Use," Transfus. Clin. Biol., 2(3): 167-179 (1995). D5 Carter, J., and H. Lutz, "An overview of viral filtration in biopharmaceutical manufacturing," European Journal of Parenteral Sciences, 7(3): 72-78 (2002). D6 Hotta, J., et al., "Significant Parvovirus Removal and Product Recovery from an IgG-containing Solution using Planova Filters," PDA/FDA Viral Clearance Forum, 1 page (October 2001). D7 Ide, S., "Development of New Planova® Membrane – the Planova® 20N Filter," Planova® Workshop Tokyo, Japan, pp. 135-145 (November 1, 2000). D8 Komeyeva, M., "Factors Influencing Virus Removal and Product Yield During Nanofiltration of Highly Purified Plasma-Derived Protein with Thrombolytic Activity," Slides from Oral Presentation, 29th World Congress of the International Society of Hematology, Seoul, Korea, pp. 1-17 (August 24-28, 2002). D9 Li, H., et al., "Low ph of Feed Solutions Significantly Increases Procine Parvovirus Aggregate Formation," Slides from Oral Presentation, PDA/FDA Viral Clearance Forum, Washington, DC, pp. 1-18 (October 1-3, 2001). D10 McNaull, S., et al., "Parvovirus Removal from an IgG-containing Solution at Extended Challenge Volume Using an Ultrafiltration Membrane in Normal-Flow Configuration," Slides from Oral Presentation, PDA/FDA Viral Clearance Forum, Washington, DC, pp. 1-12 (October 1-3, 2001). DATE CONSIDERED EXAMINER: Initial if citation considered, whether or not citation is in conformance	ADK		WO 98/37086	08/27/98	wo				_		
ADK D1		113		MENTS (Incl.	Author, Title, Date.	Pertinen	t pages, etc	2.)			
D2 Aranha, H., "Viral Clearance Strategies for Biopharmaceutical Safety Part 2: Filtration for Viral Clearance, "Reprinted from Biopharm., 8 pages (2001). D3 Burnouf-Radosevich, M., et al., "Nanofiltration, a New Specific Virus Elimination Method Applied to High-Purity Factor IX and Factor XI Concentrates," Vox. Sang., 67(1): 132-138 (1994). D4 Burnouf-Radosevich, M., "Viral Safety of Intravenous Immunglobulins G for Therapeutic Use," Transfus. Clin. Biol., 2(3): 167-179 (1995). D5 Carter, J., and H. Lutz, "An overview of viral filtration in biopharmaceutical manufacturing," European Journal of Parenteral Sciences, 7(3): 72-78 (2002). D6 Hotta, J., et al., "Significant Parvovirus Removal and Product Recovery from an IgG-containing Solution using Planova Filters," PDA/FDA Viral Clearance Forum, 1 page (October 2001). D7 Ide, S., "Development of New Planova® Membrane – the Planova® 20N Filter," Planova® Workshop Tokyo, Japan, pp. 135-145 (November 1, 2000). D8 Korneyeva, M., "Factors Influencing Virus Removal and Product Yield During Nanofiltration of Highly Purified Plasma-Derived Protein with Thrombolytic Activity," Slides from Oral Presentation, 29th World Congress of the International Society of Hematology, Seoul, Korea, pp. 1-17 (August 24-28, 2002). D9 Li, H., et al., "Low pH of Feed Solutions Significantly Increases Procine Parvovirus Aggregate Formation," Slides from Oral Presentation, PDA/FDA Viral Clearance Forum, Washington, DC, pp. 1-18 (October 1-3, 2001). D10 McNaull, S., et al., "Parvovirus Removal from an IgG-containing Solution at Extended Challenge Volume Using an Ultrafiltration Membrane in Normal-Flow Configuration," Slides from Oral Presentation, PDA/FDA Viral Clearance Forum, Washington, DC, pp. 1-12 (October 1-3, 2001). EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; draw line through citation if no		DI	Abe, H., et al., "Rem	oval of Parvov	irus B19 from Hemo	globin So	lution by N	anofilt	ration.	" Art. Co	ells.
D2 Aranha, H., "Viral Clearance Strategies for Biopharmaceutical Safety Part 2: Filtration for Viral Clearance," Reprinted from Biopharm., 8 pages (2001). D3 Burnouf-Radosevich, M., et al., "Nanofiltration, a New Specific Virus Elimination Method Applied to High-Purity Factor IX and Factor XI Concentrates," Vos. Sang., 67(I): 132-138 (1994). D4 Burnouf-Radosevich, M., "Viral Safety of Intravenous Immunglobulins G for Therapeutic Use," Transfus. Clin. Biol., 2(3): 167-179 (1995). D5 Carter, I., and H. Lutz, "An overview of viral filtration in biopharmaceutical manufacturing," European Journal of Parenteral Sciences, 7(3): 72-78 (2002). D6 Hotta, J., et al., "Significant Parvovirus Removal and Product Recovery from an IgG-containing Solution using Planova Filters," PDA/FDA Viral Clearance Forum, 1 page (October 2001). D7 Ide, S., "Development of New Planova® Membrane – the Planova® 20N Filter," Planova® Workshop Tokyo, Japan, pp. 135-145 (November 1, 2000). D8 Korneyeva, M., "Factors Influencing Virus Removal and Product Yield During Nanofiltration of Highly Purified Plasma-Derived Protein with Thrombolytic Activity," Slides from Oral Presentation, 29th World Congress of the International Society of Hematology, Seoul, Korea, pp. 1-17 (August 24-28, 2002). D9 Li, H., et al., "Low pH of Feed Solutions Significantly Increases Procine Parvovirus Aggregate Formation," Slides from Oral Presentation, PDA/FDA Viral Clearance Forum, Washington, DC, pp. 1-18 (October 1-3, 2001). D10 McNaull, S., et al., "Parvovirus Removal from an IgG-containing Solution at Extended Challenge Volume Using an Ultrafiltration Membrane in Normal-Flow Configuration," Slides from Oral Presentation, PDA/FDA Viral Clearance Forum, Washington, DC, pp. 1-12 (October 1-3, 2001). DATE CONSIDERED EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; draw line through citation if no	ADK										,
Burnouf-Radosevich, M., et al., "Nanofiltration, a New Specific Virus Elimination Method Applied to High-Purity Factor IX and Factor XI Concentrates," Vox. Sang., 67(1): 132-138 (1994). D4 Burnouf-Radosevich, M., "Viral Safety of Intravenous Immunglobulins G for Therapeutic Use," Transfus. Clin. Biol., 2(3): 167-179 (1995). D5 Carter, J., and H. Lutz, "An overview of viral filtration in biopharmaceutical manufacturing," European Journal of Parenteral Sciences, 7(3): 72-78 (2002). D6 Hotta, J., et al., "Significant Parvovirus Removal and Product Recovery from an IgG-containing Solution using Planova Filters," PDA/FDA Viral Clearance Forum, 1 page (October 2001). D7 Ide, S., "Development of New Planova® Membrane – the Planova® 20N Filter," Planova® Workshop Tokyo, Japan, pp. 135-145 (November 1, 2000). D8 Korneyeva, M., "Factors Influencing Virus Removal and Product Yield During Nanofiltration of Highly Purified Plasma-Derived Protein with Thrombolytic Activity," Slides from Oral Presentation, 29th World Congress of the International Society of Hematology, Seoul, Korea, pp. 1-17 (August 24-28, 2002). D9 Li, H., et al., "Low pH of Feed Solutions Significantly Increases Procine Parvovirus Aggregate Formation," Slides from Oral Presentation, PDA/FDA Viral Clearance Forum, Washington, DC, pp. 1-18 (October 1-3, 2001). D10 McNaull, S., et al., "Parvovirus Removal from an IgG-containing Solution at Extended Challenge Volume Using an Ultrafiltration Membrane in Normal-Flow Configuration," Slides from Oral Presentation, PDA/FDA Viral Clearance Forum, Washington, DC, pp. 1-12 (October 1-3, 2001). EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; draw line through citation if no		D2	Aranha, H., "Viral Clearance Strategies for Biopharmaceutical Safety Part 2: Filtration for Viral								
Burnouf-Radosevich, M., "Viral Safety of Intravenous Immunglobulins G for Therapeutic Use," Transfus. Clin. Biol., 2(3): 167-179 (1995). D5 Carter, J., and H. Lutz, "An overview of viral filtration in biopharmaceutical manufacturing," European Journal of Parenteral Sciences, 7(3): 72-78 (2002). D6 Hotta, J., et al., "Significant Parvovirus Removal and Product Recovery from an IgG-containing Solution using Planova Filters," PDA/FDA Viral Clearance Forum, 1 page (October 2001). D7 Ide, S., "Development of New Planova® Membrane – the Planova® 20N Filter," Planova® Workshop Tokyo, Japan, pp. 135-145 (November 1, 2000). D8 Korneyeva, M., "Factors Influencing Virus Removal and Product Yield During Nanofiltration of Highly Purified Plasma-Derived Protein with Thrombolytic Activity," Slides from Oral Presentation, 29th World Congress of the International Society of Hematology, Seoul, Korea, pp. 1-17 (August 24-28, 2002). D9 Li, H., et al., "Low pH of Feed Solutions Significantly Increases Procine Parvovirus Aggregate Formation," Slides from Oral Presentation, PDA/FDA Viral Clearance Forum, Washington, DC, pp. 1-18 (October 1-3, 2001). D10 McNaull, S., et al., "Parvovirus Removal from an IgG-containing Solution at Extended Challenge Volume Using an Ultrafiltration Membrane in Normal-Flow Configuration," Slides from Oral Presentation, PDA/FDA Viral Clearance Forum, Washington, DC, pp. 1-12 (October 1-3, 2001). EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; draw line through citation if no		D3	Burnouf-Radosevich, M., et al., "Nanofiltration, a New Specific Virus Elimination Method Applied to								
D5 Carter, J., and H. Lutz, "An overview of viral filtration in biopharmaceutical manufacturing," European Journal of Parenteral Sciences, 7(3): 72-78 (2002). D6 Hotta, J., et al., "Significant Parvovirus Removal and Product Recovery from an IgG-containing Solution using Planova Filters," PDA/FDA Viral Clearance Forum, 1 page (October 2001). D7 Ide, S., "Development of New Planova® Membrane – the Planova® 20N Filter," Planova® Workshop Tokyo, Japan, pp. 135-145 (November 1, 2000). D8 Korneyeva, M., "Factors Influencing Virus Removal and Product Yield During Nanofiltration of Highly Purified Plasma-Derived Protein with Thrombolytic Activity," Slides from Oral Presentation, 29th World Congress of the International Society of Hematology, Seoul, Korea, pp. 1-17 (August 24-28, 2002). D9 Li, H., et al., "Low pH of Feed Solutions Significantly Increases Procine Parvovirus Aggregate Formation," Slides from Oral Presentation, PDA/FDA Viral Clearance Forum, Washington, DC, pp. 1-18 (October 1-3, 2001). D10 McNaull, S., et al., "Parvovirus Removal from an IgG-containing Solution at Extended Challenge Volume Using an Ultrafiltration Membrane in Normal-Flow Configuration," Slides from Oral Presentation, PDA/FDA Viral Clearance Forum, Washington, DC, pp. 1-12 (October 1-3, 2001). EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; draw line through citation if no		D4 ,	Burnouf-Radosevich, M., "Viral Safety of Intravenous Immunglobulins G for Therapeutic Use," Transfus.								
Hotta, J., et al., "Significant Parvovirus Removal and Product Recovery from an IgG-containing Solution using Planova Filters," PDA/FDA Viral Clearance Forum, 1 page (October 2001). D7 Ide, S., "Development of New Planova® Membrane – the Planova® 20N Filter," Planova® Workshop Tokyo, Japan, pp. 135-145 (November 1, 2000). D8 Korneyeva, M., "Factors Influencing Virus Removal and Product Yield During Nanofiltration of Highly Purified Plasma-Derived Protein with Thrombolytic Activity," Slides from Oral Presentation, 29th World Congress of the International Society of Hematology, Seoul, Korea, pp. 1-17 (August 24-28, 2002). D9 Li, H., et al., "Low pH of Feed Solutions Significantly Increases Procine Parvovirus Aggregate Formation," Slides from Oral Presentation, PDA/FDA Viral Clearance Forum, Washington, DC, pp. 1-18 (October 1-3, 2001). D10 McNaull, S., et al., "Parvovirus Removal from an IgG-containing Solution at Extended Challenge Volume Using an Ultrafiltration Membrane in Normal-Flow Configuration," Slides from Oral Presentation, PDA/FDA Viral Clearance Forum, Washington, DC, pp. 1-12 (October 1-3, 2001). EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; draw line through citation if no		D5	Carter, J., and H. Lutz, "An overview of viral filtration in biopharmaceutical manufacturing," European								
D7 Ide, S., "Development of New Planova® Membrane – the Planova® 20N Filter," Planova® Workshop Tokyo, Japan, pp. 135-145 (November 1, 2000). D8 Korneyeva, M., "Factors Influencing Virus Removal and Product Yield During Nanofiltration of Highly Purified Plasma-Derived Protein with Thrombolytic Activity," Slides from Oral Presentation, 29th World Congress of the International Society of Hematology, Seoul, Korea, pp. 1-17 (August 24-28, 2002). D9 Li, H., et al., "Low pH of Feed Solutions Significantly Increases Procine Parvovirus Aggregate Formation," Slides from Oral Presentation, PDA/FDA Viral Clearance Forum, Washington, DC, pp. 1-18 (October 1-3, 2001). McNaull, S., et al., "Parvovirus Removal from an IgG-containing Solution at Extended Challenge Volume Using an Ultrafiltration Membrane in Normal-Flow Configuration," Slides from Oral Presentation, PDA/FDA Viral Clearance Forum, Washington, DC, pp. 1-12 (October 1-3, 2001). EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; draw line through citation if no		D6	Hotta, J., et al., "Significant Parvovirus Removal and Product Recovery from an IgG-containing Solution								
Korneyeva, M., "Factors Influencing Virus Removal and Product Yield During Nanofiltration of Highly Purified Plasma-Derived Protein with Thrombolytic Activity," Slides from Oral Presentation, 29th World Congress of the International Society of Hematology, Seoul, Korea, pp. 1-17 (August 24-28, 2002). D9 Li, H., et al., "Low pH of Feed Solutions Significantly Increases Procine Parvovirus Aggregate Formation," Slides from Oral Presentation, PDA/FDA Viral Clearance Forum, Washington, DC, pp. 1-18 (October 1-3, 2001). D10 McNaull, S., et al., "Parvovirus Removal from an IgG-containing Solution at Extended Challenge Volume Using an Ultrafiltration Membrane in Normal-Flow Configuration," Slides from Oral Presentation, PDA/FDA Viral Clearance Forum, Washington, DC, pp. 1-12 (October 1-3, 2001). EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; draw line through citation if no		D7	Ide, S., "Developmen	nt of New Planc	ova® Membrane - the				inova	® Works	hop
Purified Plasma-Derived Protein with Thrombolytic Activity," Slides from Oral Presentation, 29th World Congress of the International Society of Hematology, Seoul, Korea, pp. 1-17 (August 24-28, 2002). D9 Li, H., et al., "Low pH of Feed Solutions Significantly Increases Procine Parvovirus Aggregate Formation," Slides from Oral Presentation, PDA/FDA Viral Clearance Forum, Washington, DC, pp. 1-18 (October 1-3, 2001). D10 McNaull, S., et al., "Parvovirus Removal from an IgG-containing Solution at Extended Challenge Volume Using an Ultrafiltration Membrane in Normal-Flow Configuration," Slides from Oral Presentation, PDA/FDA Viral Clearance Forum, Washington, DC, pp. 1-12 (October 1-3, 2001). EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; draw line through citation if no	- 	Do .	Lokyo, Japan, pp. 133-143 (November 1, 2000). Korneyaya M. "Factors Influencing Virus Removal and Broduct Viold During Nanofiltration of Ulabla.								
Congress of the International Society of Hematology, Seoul, Korea, pp. 1-17 (August 24-28, 2002). D9 Li, H., et al., "Low pH of Feed Solutions Significantly Increases Procine Parvovirus Aggregate Formation," Slides from Oral Presentation, PDA/FDA Viral Clearance Forum, Washington, DC, pp. 1-18 (October 1-3, 2001). D10 McNaull, S., et al., "Parvovirus Removal from an IgG-containing Solution at Extended Challenge Volume Using an Ultrafiltration Membrane in Normal-Flow Configuration," Slides from Oral Presentation, PDA/FDA Viral Clearance Forum, Washington, DC, pp. 1-12 (October 1-3, 2001). EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; draw line through citation if no	ı	מת									
Li, H., et al., "Low pH of Feed Solutions Significantly Increases Procine Parvovirus Aggregate Formation," Slides from Oral Presentation, PDA/FDA Viral Clearance Forum, Washington, DC, pp. 1-18 (October 1-3, 2001). D10 McNaull, S., et al., "Parvovirus Removal from an IgG-containing Solution at Extended Challenge Volume Using an Ultrafiltration Membrane in Normal-Flow Configuration," Slides from Oral Presentation, PDA/FDA Viral Clearance Forum, Washington, DC, pp. 1-12 (October 1-3, 2001). EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; draw line through citation if no											
Slides from Oral Presentation, PDA/FDA Viral Clearance Forum, Washington, DC, pp. 1-18 (October 1-3, 2001). D10 McNaull, S., et al., "Parvovirus Removal from an IgG-containing Solution at Extended Challenge Volume Using an Ultrafiltration Membrane in Normal-Flow Configuration," Slides from Oral Presentation, PDA/FDA Viral Clearance Forum, Washington, DC, pp. 1-12 (October 1-3, 2001). EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; draw line through citation if no		D9									
McNaull, S., et al., "Parvovirus Removal from an IgG-containing Solution at Extended Challenge Volume Using an Ultrafiltration Membrane in Normal-Flow Configuration," Slides from Oral Presentation, PDA/FDA Viral Clearance Forum, Washington, DC, pp. 1-12 (October 1-3, 2001). EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; draw line through citation if no		-	Slides from Oral Pre								·
Using an Ultrafiltration Membrane in Normal-Flow Configuration," Slides from Oral Presentation, PDA/FDA Viral Clearance Forum, Washington, DC, pp. 1-12 (October 1-3, 2001). EXAMINER EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; draw line through citation if no	————	D10		Parvovirus Ren	noval from an IgG-co	ntaining	Solution at	Extend	ed Ch	allenge	Volume
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; draw line through citation if no	ADK		Using an Ultrafiltrati	on Membrane i	in Normal-Flow Conf	figuration	" Slides fro	om Ora			
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; draw line through citation if no		<u> </u>	PDA/FDA Viral Clea	arance Forum,				2001).			-
	EXAMINER				DATE	CONSIL	DERED '				
	EXAMINER:	Initial if c	citation considered, who	ther or not cita	tion is in conformance	e with M	PEP 609; d	lraw lin	e thro	ugh citat	tion if not
										-	

FORM PTO -1449 U.S. DEPARTMENT OF COMM PATENT AND TRADEMARK O			ATTY DKT NO. B185 1180.1	SERIAL NO. 10/670,896					
		NFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	APPLICANT Hotta, et al. FILING DATE	GROUP.					
			09/25/03	3762					
		OTHER DOCUMENTS (Including Author	r, Title, Date, Pertinent Pages,	etc.)					
ADK _.	DII	O'Grady, J., et al., "Virus Removal Studies Using Nand Clearance from Biopharmaceutical Products, Dev. Biol.		nd Evaluation of Viral					
	D12	Omar, A., and C. Kempf, "Removal of Neutralized Mo Nanofiltration, <i>Transfusion</i> , 42: 1005-1010 (2002).	del Parvoviruses and Enteroviruses in	Human IgG Solutions by					
	D13	Troccoli, N.M., et al., "Removal of Viruses from Human Intravenous Immune Globulin by 35 nm Nanofiltration," Biologicals, 26: 321-329 (1998).							
	D14	Planova® Filters, Planova® Filters for Virus Removal, Asahi Kasei Corporation, Planova® Division, 4 pages, www.asahi-kasei.co.jp/planova/product/filters.html (date of public availability unknown).							
	D15	Section 3.1. <u>Virus validation studies for Parvovirus B19</u> , Plasma Protein Therapeutics Association Europe, pp. 5-9 (February 14, 2000).							
	D16	Planova® Workshop 2002, Biotherapeutic Production, Bethesda, Maryland, USA, Asahi Kasei Corporation, et		Filtration Products,					
	D17	Planova® Workshop 2001, Virus removal filtration: ap Asahi Kasei Corporation, entire publication, (September		ontecatini Terme, Italy,					
	D18	Planova® Workshop Japan, A forum for exchanging in Tokyo, Japan, Asahi Kasei Corporation, entire publicat		n virus removal filtration					
	D19	Planova® Workshop USA '99, A forum for exchanging information on the latest developments in virus removal technology, Washington, DC, USA, Asahi Chemical Industry Co., Ltd., entire publication, (November 29, 1999).							
ADK	D20	Planova™ Workshop, To meet and exchange informati Oslo, Norway, Asahi Chemical Industry Co., Ltd., entir		removal technology,					
EXAMINE	R	/Andrew D. Kosar/	DATE CONSIDERED 05/26/2	006					
		al if citation considered, whether or not citation is in con ot considered. Include copy of this form with next comm		hrough citation if not in					